Medtronic/VidaMed
This article was originally published in The Gray Sheet
Executive Summary
Pending VidaMed shareholder complaint that Medtronic's $326 mil., $7.91-per-share cash acquisition deal is inadequate is without merit, VidaMed says (1"The Gray Sheet," Dec. 10, 2001, p. 18). Filed Dec. 7 in the Delaware Court of Chancery, the complaint alleges that Medtronic was able to use its minority stake in the company to compel VidaMed's board to accept a less than fair acquisition price. The $7.91 per share deal represents a 40% premium to its pre-announcement close...
You may also be interested in...
FDA Commissioner Search: ACLA Head Sundwall Contacted By White House
American Clinical Laboratory Association President David Sundwall, MD, says he has been contacted twice recently by the White House to determine his interest in becoming the next FDA commissioner
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.